Skip to main content

Day: April 20, 2022

Host Hotels & Resorts Disposes of Sheraton New York Times Square Hotel

BETHESDA, Md., April 20, 2022 (GLOBE NEWSWIRE) — Host Hotels & Resorts, Inc. (NASDAQ: HST), the nation’s largest lodging real estate investment trust (the “Company”), today announced that it has sold the 1,780-room Sheraton New York Times Square Hotel for approximately $373 million, which represents a 28.0x EBITDA multiple1 on 2019 EBITDA. The EBITDA multiple includes approximately $136 million of estimated foregone capital expenditures over the next five years. In connection with the sale, the Company is providing a $250 million bridge loan to the purchaser. James F. Risoleo, president and chief executive officer, said, “The sale of the Sheraton New York Times Square Hotel represents another important step in the transformation of our portfolio as we look to deploy capital into assets that will bolster our...

Continue reading

Rain Therapeutics to Report First Quarter 2022 Financial Results and Highlights of Recent Progress on May 4, 2022

NEWARK, Calif., April 20, 2022 (GLOBE NEWSWIRE) — Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced it will report financial results for the first quarter ended March 31, 2022 and highlights of recent progress on Wednesday, May 4, 2022. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company’s business and financial results. Conference Call and Webcast Details: Date: May 4, 2022Time: 2:00-3:00 pm PT (5:00-6:00 pm ET)Dial In Numbers: 1 (877) 300-8521 (U.S. Toll Free) / 1 (412) 317-6026 (International) Conference ID: 10166166 Webcast Link: https://services.choruscall.com/mediaframe/webcast.html?webcastid=yOa8KoUv Replay of the call will be available by visiting the “Events” section...

Continue reading

Certara to Report First Quarter 2022 Financial Results on May 5th, 2022

PRINCETON, N.J., April 20, 2022 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2022 after the market close on Thursday, May 5th, 2022. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing (833) 360-0946 for domestic callers or (914) 987-7661 for international callers, followed by Conference ID: 1290087. A live and archived webcast of the event will be available on the “Investors” section of the Certara website at https://ir.certara.com/. About CertaraCertara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development....

Continue reading

Sportradar to Release First Quarter 2022 Earnings on May 18, 2022

NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) — Sportradar Group AG (NASDAQ:SRAD) (“Sportradar” or “the Company”), will release its financial and operating results for the first quarter fiscal 2022, ending March 31, 2022, on Wednesday, May 18, 2022. Sportradar will also host a conference call to discuss these results at 8:00 a.m. eastern time on Wednesday, May 18, 2022. Those wishing to participate via webcast should access the earnings call through Sportradar’s Investor Relations website at https://investors.sportradar.com/. An archived webcast with the accompanying slides will be available at the Company’s investor relations website for one year after the conclusion of the live event. Those wishing to participate via telephone may dial in at 1-855-725-1617 (USA) or +1-509-960-9043 (International), passcode 4366155. A replay of the...

Continue reading

Eyenovia CEO, CMO and Chairman Dr. Sean Ianchulev to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022

Presentation to review historic issues related to glaucoma therapies and how these may be addressed through the use of Optejet® technology NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) investigational products, today announced that Dr. Sean Ianchulev, Chairman, Chief Executive Officer and Chief Medical Officer, will deliver a presentation at Eyecelerator, which is being held on Thursday, April 21 in Washington, DC. “I am very pleased to have this opportunity to present at this year’s Eyecelerator conference and highlight new data demonstrating the many aspects of our proprietary Optejet® technology. We believe the Optejet® coupled with an effective IOP lowering medication may be able to address the...

Continue reading

Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta

Global study will evaluate UX143 in pediatric and young adult patients ages 5 to NOVATO, Calif., April 20, 2022 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced the first patient has been dosed in a clinical study for the treatment of Osteogenesis Imperfecta (OI) in patients ages 5 to

Continue reading

GWG Holdings Undertakes Financial Restructuring

Obtains Debtor-In-Possession Financing to Facilitate Restructuring Expects Restructuring to Strengthen Financial Position and Enhance Value of its Assets DALLAS, April 20, 2022 (GLOBE NEWSWIRE) — GWG Holdings, Inc. (Nasdaq GWGH) (the “Company”), a financial services firm based in Dallas, Texas, today announced that the Company and certain of its subsidiaries have filed voluntary Chapter 11 petitions (the “Chapter 11 Cases”) in the U.S. Bankruptcy Court for the Southern District of Texas (the “Court”) as part of a restructuring process intended to enable the Company to enhance its liquidity and ability to meet its financial obligations, while maximizing the value of its assets. The subsidiaries that are debtors in the Chapter 11 Cases are GWG Life, LLC and GWG Life USA, LLC (together with the Company, the “Debtors”). The Company...

Continue reading

ARKO to Report First Quarter 2022 Financial Results on May 4, 2022

RICHMOND, Va., April 20, 2022 (GLOBE NEWSWIRE) — ARKO Corp. (Nasdaq: ARKO) (the “Company”) today announced that the Company will report results for the first quarter ended March 31, 2022 on Wednesday, May 4, 2022 before the markets open in the United States. The Company will host a conference call to discuss these results at 10:00 a.m. Eastern Time on May 4, 2022. Investors interested in participating in the live call can dial 877-605-1792 or 201-689-8728. A telephone replay will be available approximately two hours after the call concludes through May 18, 2022, by dialing 877-660-6853 or 201-612-7415 and entering confirmation code 13729048. There will also be a simultaneous, live webcast available on the Investor Relations section of the Company’s website at https://www.arkocorp.com/. The webcast will be archived for 30 days. About...

Continue reading

Healthcare Triangle Achieves HITRUST Risk-based, 2-year Certification to Manage Risk, Improve Security Posture, and Meet Compliance Requirements

HITRUST Risk-based, 2-year Certification validates Healthcare Triangle is committed to meeting key regulations and protecting sensitive information PLEASANTON, Calif., April 20, 2022 (GLOBE NEWSWIRE) — Healthcare Triangle Inc., (Nasdaq: HCTI) (“HCTI” or the “Company”), a leading provider of cloud and data transformation solutions for healthcare and life sciences, today announced its Cloud and Data Platform (CaDP) hosted on Amazon Web Services (AWS) and the supporting network infrastructure hosted on the O365 Cloud has earned Certified status for information security by HITRUST. HITRUST Risk-based, 2-year (r2) Certified status demonstrates that HCTI’s Cloud and Data Platform (CaDP) has met key regulations and industry-defined requirements and is appropriately managing risk. This achievement places Healthcare Triangle...

Continue reading

eXp Realty Celebrates 80,000 Real Estate Agents as Brokerage Continues Worldwide Expansion

eXp Realty Exceeds 80,000 Real Estate Agents Worldwide eXp Realty Celebrates 80,000 Real Estate Agents as Brokerage Continues Worldwide ExpansionMilestone Represents Continued Growth as Company Expects to Surpass 100,000 Agents in 2022 Glenn Sanford to Speak Today at Inman Connect New York on the Merits of Growth-Oriented, Accessible Leadership BELLINGHAM, Wash., April 20, 2022 (GLOBE NEWSWIRE) — eXp Realty®, the fastest-growing global real estate brokerage and the core subsidiary of eXp World Holdings, Inc. (Nasdaq: EXPI), today announced it has exceeded 80,000 agents globally, representing an increase of 50% when compared to 53,379 agents in April 2021. Also today, Glenn Sanford, Founder, CEO and Chairman of eXp World Holdings, will take the stage at Inman Connect New York to talk about the accessible leadership traits that...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.